Novo Nordisk Stock Faces a Pivotal Crossroads: Pipeline Data, Medicare Entry, and India Approval Collide

Novo Nordisk enters a defining stretch with three catalysts: CagriSema Phase 3 results at ADA, India's Wegovy approval for adolescents, and Medicare coverage at $50/month starting July 1.

Novo Nordisk enters a defining stretch next week with three major catalysts converging almost simultaneously, offering the beaten-down Danish drugmaker a chance to rewrite its narrative. The company will unveil a broad slate of clinical data at the American Diabetes Association’s Scientific Sessions in New Orleans from June 5 to 8, host a dedicated R&D investor day on June 7, and see its blockbuster obesity drug Wegovy enter Medicare coverage on July 1 for just $50 a month. Meanwhile, news broke that Indian regulators have cleared Wegovy for adolescents aged 12 and older weighing more than 60 kilograms, handing Novo a fresh foothold in a market where Eli Lilly’s Mounjaro has been outselling it.

The ADA conference will feature 40 abstracts, headlined by pivotal Phase 3 results from the REIMAGINE 1–3 studies of CagriSema, a fixed-dose combination of an amylin receptor agonist and a GLP-1 receptor agonist targeting both blood sugar control and weight loss in Type 2 diabetes. Previously released data from the REIMAGINE-2 study showed CagriSema lowered HbA1c by 1.91 percentage points after 68 weeks, with patients shedding an average of 14.2% of their body weight. Forty-three percent of participants achieved weight loss of at least 15%. Novo will also present Phase 2 data on injectable Zenagamtid — formerly known as Amycretin — a once-weekly dual GLP-1 and amylin agonist designed to go beyond conventional semaglutide therapies and underpin the next generation of obesity treatments.

The India approval broadens Wegovy’s label beyond adults for the first time and offers a strategic counterweight. Lilly’s Mounjaro has so far captured more injectable market share in India, but it lacks an adolescent indication. While the revenue contribution from younger patients alone is unlikely to move the needle, the clearance strengthens Novo’s ability to differentiate its GLP-1 franchise in a price-sensitive, increasingly competitive market. The move also aligns with a broader push to defend the portfolio through additional indications and expanded labeling.

On the commercial front, the Medicare GLP-1 Bridge program marks a historic shift. Starting July 1, eligible Medicare beneficiaries with obesity will gain access to Wegovy injections and tablets for a $50 monthly copay, running through the end of 2027 across all states and territories. It ends a two-decade federal ban on Medicare covering prescription drugs specifically for weight loss. Novo Nordisk and Lilly have agreed to supply the drugs at a net price of $245 per month, well below list prices exceeding $1,000. The program is expected to unlock significant demand but also adds pressure on realized pricing.

Novo Nordisk is also leaning on share buybacks to support the stock. The company reported progress on May 26 on a 15 billion Danish krone repurchase program that began on February 4, 2026. As of May 22, it had bought back 17.05 million B-shares at an average price of 262.22 kroner, for a total of 4.47 billion kroner. A separate program launched on May 6 allows for up to 11.2 billion kroner in B-share buybacks through February 1, 2027. The treasury now holds 34.23 million B-shares, or 0.8% of share capital.

Despite these tailwinds, the stock remains deep in the red. It closed Friday at €39.05, nearly flat, but has lost 35.7% over the past 12 months. The 52-week high of €70.13 sits 44.3% above the current price, though the stock has recovered 28.1% from its March low of €30.48 on growing optimism over the obesity pill pipeline. Analysts remain cautious: Citi raised its price target to 290 kroner from 275 but kept a neutral rating. Deutsche Bank and Jefferies also maintained hold ratings, with Jefferies’ Michael Leuchten setting a target of 270 kroner — below the last close of 292.95 kroner in Copenhagen.

Underlying the stock’s struggle are persistent margin and pricing headwinds. Novo’s adjusted revenue excluding a 340B specialty effect fell 4% on a currency-adjusted basis in the first quarter, even as obesity product sales rose 22%. The company forecasts a currency-adjusted decline of 4% to 12% in both revenue and operating profit for 2026. The POSEIDON observational study, covering 18,904 patients in 18 countries, underscored the unmet need: two out of five patients with atherosclerotic cardiovascular disease and chronic kidney disease still had elevated inflammation (hsCRP ?2 mg/L) despite standard therapy.

The coming weeks will test whether the combination of pipeline data, Medicare expansion, regulatory wins, and buybacks can outweigh the structural pressure on profits. Novo Nordisk’s story remains split — compelling medical advances and a strong obesity pipeline on one side, a shrinking earnings lever on the other.